Sections
| Title | Starting Page | Number of Pages |
|---|
| Table of Contents | 5 | 7 |
| List of Tables | 7 | 2 |
| List of Figures | 9 | 3 |
| Emerging Pharmaceutical Market - Indonesia and the Philippines -Introduction | 12 | 1 |
| Emerging Pharmaceutical Market - Indonesia and the Philippines Industry Characterstics | 13 | 30 |
| Market Size and Market Forecast | 13 | 1 |
| Indonesia | 13 | 2 |
| The Philippines | 15 | 2 |
| Market Share by Therapeutic Area | 17 | 1 |
| Indonesia | 17 | 1 |
| Context | 17 | 2 |
| The Philippines | 19 | 1 |
| Market Share Branded versus Generic Market Share | 20 | 1 |
| Indonesia | 20 | 1 |
| The Philippines | 21 | 1 |
| Top Five Pharmaceutical Companies, Market Share | 22 | 1 |
| Indonesia | 22 | 1 |
| PT. Kalbe Farma Tbk | 23 | 1 |
| Dexa Medica | 24 | 1 |
| Sanbe Farma | 25 | 1 |
| PT. SOHO Industri Pharmasi | 26 | 1 |
| PT Tempo Scan Pacific Tbk. | 27 | 1 |
| The Philippines | 28 | 1 |
| UNILAB | 29 | 1 |
| GlaxoSmithKline (GSK) | 30 | 1 |
| Euro-Med Lab | 31 | 1 |
| Pfizer Inc. | 32 | 1 |
| Bristol Myers Squibb | 33 | 1 |
| R&D Expenditure and Innovations | 34 | 1 |
| Indonesia | 34 | 1 |
| The Philippines | 34 | 1 |
| Trends and Recent Developments in Foreign Direct Investment | 35 | 1 |
| Indonesia | 35 | 1 |
| The Philippines | 35 | 1 |
| Marketing Distribution Channel | 36 | 1 |
| Indonesia | 36 | 1 |
| The Philippines | 37 | 1 |
| PESTLE Analysis | 38 | 1 |
| Indonesia | 38 | 1 |
| Political Factors | 38 | 1 |
| Economic Factors | 39 | 1 |
| Social Factors | 39 | 1 |
| Technological Factors | 39 | 1 |
| Legal Factors | 39 | 1 |
| Environmental Factors | 40 | 1 |
| The Philippines | 40 | 1 |
| Political Factors | 40 | 1 |
| Economic Factors | 41 | 1 |
| Social Factors | 41 | 1 |
| Technological Factors | 41 | 1 |
| Legal Factors | 42 | 1 |
| Environmental Factors | 42 | 1 |
| Emerging Pharmaceutical Market - Indonesia and the Philippines Macroeconomic Environment | 43 | 16 |
| Demographic Analysis | 43 | 1 |
| Population Size, Growth, and Structure | 43 | 1 |
| Indonesia | 43 | 3 |
| The Philippines | 46 | 1 |
| Mortality Rate | 47 | 1 |
| Population Ageing and Health | 48 | 1 |
| Indonesia | 48 | 1 |
| The Philippines | 48 | 1 |
| GDP | 49 | 1 |
| Indonesia | 49 | 2 |
| The Philippines | 51 | 2 |
| Per Capita Income | 53 | 1 |
| Indonesia | 53 | 1 |
| The Philippines | 54 | 1 |
| Income Status | 55 | 1 |
| Indonesia | 55 | 1 |
| The Philippines | 55 | 1 |
| Healthcare Expenditure | 56 | 1 |
| Context | 56 | 1 |
| Healthcare Infrastructure | 57 | 1 |
| Context | 57 | 1 |
| Number of Active Physicians and Hospital Beds | 57 | 1 |
| Analytical Framework | 58 | 1 |
| Indonesia, Number of Hospitals | 58 | 1 |
| The Philippines, Number of Hospitals | 58 | 1 |
| Emerging Pharmaceutical Market - Indonesia and The Philippines Healthcare Regulation | 59 | 11 |
| Pharmaceutical Regulation in Indonesia and the Philippines | 59 | 1 |
| Healthcare System Structure | 59 | 1 |
| Indonesia | 59 | 1 |
| The Philippines | 60 | 1 |
| Drug Approval Process | 61 | 1 |
| Indonesia | 61 | 1 |
| The Philippines | 62 | 1 |
| Requirements for Product Registration with the Bureau of Food and Drugs (BFAD) | 62 | 1 |
| Procedure for Product Registration with the BFAD | 62 | 1 |
| Patents and Generics (IPR) | 63 | 1 |
| Context | 63 | 1 |
| Indonesia | 63 | 1 |
| The Philippines | 63 | 1 |
| Analytical Framework | 64 | 1 |
| Health Insurance Coverage | 65 | 1 |
| Indonesia | 65 | 1 |
| The Philippines | 65 | 1 |
| Clinical Trials | 66 | 1 |
| Context | 66 | 1 |
| Indonesia | 66 | 1 |
| The Philippines | 67 | 1 |
| Analytical Framework | 67 | 1 |
| Pricing and Reimbursement | 68 | 1 |
| Context | 68 | 1 |
| Indonesia | 68 | 1 |
| The Philippines | 69 | 1 |
| Emerging Pharmaceutical Market - Indonesia and the Philippines Industry Trends | 70 | 22 |
| Deals by Type | 70 | 1 |
| Indonesia | 70 | 1 |
| The Philippines | 71 | 1 |
| Mergers and Acquisitions | 72 | 1 |
| Deals by Year | 72 | 1 |
| Indonesia | 72 | 1 |
| The Philippines | 73 | 1 |
| Deal by Value | 74 | 1 |
| Indonesia | 74 | 1 |
| The Philippines | 75 | 1 |
| Indonesia and the Philippines Top Five M&A Deals | 76 | 1 |
| Meda Acquires Commercializtion Rights of Sublinox and OX-NLA from Orexo | 76 | 1 |
| GlaxoSmithKline Acquires Pharmaceutical Brands from UCB | 77 | 1 |
| Prosidion Completes Sale of Dipeptidyl Peptidase IV Patent Estate and Associated Royalty Interest to Royalty Pharma | 77 | 1 |
| Meda Completes Acquisition of Global Rights to Elidel from Novartis | 77 | 1 |
| 3M Sells Pharmaceuticals Business in Asia-Pacific Region | 77 | 1 |
| Licensing Agreements | 78 | 1 |
| Deals by Year | 78 | 1 |
| Indonesia | 78 | 1 |
| The Philippines | 79 | 1 |
| Deals by Value | 80 | 1 |
| Indonesia | 80 | 1 |
| The Philippines | 81 | 1 |
| Indonesia and the Philippines Top Five Licensing Deals | 82 | 1 |
| Cephalon Enters into Licensing Agreement with Mesoblast | 82 | 1 |
| F-star Biotechnologische Enters into Licensing Agreement with Boehringer Ingelheim | 83 | 1 |
| Galapagos Enters into Licensing Agreement with Eli Lilly and Company | 83 | 1 |
| Vertex Pharmaceuticals Enters into Licensing Agreement with Alios BioPharma for ALS-2200 and ALS-2158 | 84 | 1 |
| PTC Therapeutics Enters into Licensing Agreement with Pfizer | 84 | 1 |
| Co-Development Deals | 85 | 1 |
| By Year | 85 | 1 |
| Indonesia | 85 | 1 |
| The Philippines | 86 | 1 |
| By Value | 87 | 1 |
| Indonesia | 87 | 1 |
| The Philippines | 88 | 1 |
| Indonesia and the Philippines Top Five Co-Development Deals | 89 | 1 |
| Eli Lilly Enters into Co-Development Agreement with Boehringer Ingelheim | 89 | 1 |
| Boehringer Ingelheim Enters into Co-Development Agreement with MacroGenics | 90 | 1 |
| GlaxoSmithKline Enters into Co-Development Agreement with ChemoCentryx | 90 | 1 |
| GlaxoSmithKline Signs an Agreement with OncoMed Pharmaceuticals | 91 | 1 |
| GlaxoSmithKline Enters into Collaboration with Synta Pharmaceuticals for STA-4783 | 91 | 1 |
| Emerging Pharmaceutical Market - Indonesia and The Philippines Service Industries CMO, CRO | 92 | 3 |
| Clinical Research Organization (CRO) | 92 | 1 |
| Indonesia CRO PEST Analysis | 92 | 1 |
| Philippines CRO PEST Analysis | 93 | 1 |
| Contract Manufacturing Organization (CMO) | 93 | 1 |
| Indonesia CMO PEST Analysis | 93 | 1 |
| The Philippines CMO PEST Analysis | 94 | 1 |
| Appendix | 95 | 4 |
| Market Definitions | 95 | 1 |
| Abbreviations | 95 | 1 |
| Sources | 96 | 1 |
| Research Methodology | 96 | 2 |
| Industry Characteristics | 97 | 1 |
| Demographic Analysis | 97 | 1 |
| Healthcare Regulation | 97 | 1 |
| Industry Trends | 97 | 1 |
| Service Industries CMO, CRO | 97 | 1 |
| Contact Us | 97 | 1 |
| Disclaimer | 98 | 1 |